Sentences with phrase «studies on drug»

Therefore, studies on drug use were excluded as well as studies on delinquency, except if drug use or delinquency was part of an instrument measuring externalizing problems.

For example, NHTSA recently released the results of two major studies on drug use by drivers: the «2013 - 2014 National Roadside Survey of Alcohol» and «Drug and Alcohol Crash Risk.»

This was due to a result of tumors, which came about during animal studies on the drug.

The determination of each efficacy level was also based on the rigor and quantity of published studies on the drug class: to be in Level A, for example, a class of drugs must have been supported by at least two «Class I» studies — well - designed, double - blind, randomized, placebo - controlled clinical trials.

Darshak Sanghavi, chief of pediatric cardiology at the University of Massachusetts Medical School in Worcester, notes that although the FDA has approved some statins for use in children with a genetic problem leading to high cholesterol, there are no studies on the drugs» long - term side effects in children.

«Eliminating cost barriers helps heart patients comply with drug regimens: Study on drug adherence provides insights on prescribing patterns and clinical outcomes.»

Study on drug - guide effect of Achyranthes bidentata in Sanmiao pill in rats, Zhongguo Zhong Yao Za Zhi, 2008 DecPubmed ID: 19294858 3.

Rob developed innovative methods for monitoring the quality of pharmaceuticals during manufacturing and completed an extensive study on drug stability.

So, if I publish a study on a drug produced by Glaxo and I own $ 10,000 stock in Glaxo, most journals would require me to disclose that.

Not exact matches

While the new mid-stage study results from DNDi were impressive (they showed cure rates of 96 % to 97 % even for the sickest patients and those with liver scarring), more late - stage trials will be necessary before the drug is available on a large scale in the developing world.

A new study published in the New England Journal of Medicine finds that Valeant Pharmaceuticals» infamous price hikes for a pair of heart drugs called nitroprusside and isoproterenol — whose prices were increased by 310 % and 720 %, respectively — had significant downstream effects on patient care.

The striking example I focused on then was the cancer drug Avastin, developed by Genentech (now Roche)-- which, at the time, had been studied in at least 400 completed human clinical trials for various cancers.

Topics included: early reporting on inaccuracies in the articles of The New York Times's Judith Miller that built support for the invasion of Iraq; the media campaign to destroy UN chief Kofi Annan and undermine confidence in multilateral solutions; revelations by George Bush's biographer that as far back as 1999 then - presidential candidate Bush already spoke of wanting to invade Iraq; the real reason Bush was grounded during his National Guard days — as recounted by the widow of the pilot who replaced him; an article published throughout the world that highlighted the West's lack of resolve to seriously pursue the genocidal fugitive Bosnian Serb leader Radovan Karadzic, responsible for the largest number of European civilian deaths since World War II; several investigations of allegations by former members concerning the practices of Scientology; corruption in the leadership of the nation's largest police union; a well - connected humanitarian relief organization operating as a cover for unauthorized US covert intervention abroad; detailed evidence that a powerful congressional critic of Bill Clinton and Al Gore for financial irregularities and personal improprieties had his own track record of far more serious transgressions; a look at the practices and values of top Democratic operative and the clients they represent when out of power in Washington; the murky international interests that fueled both George W. Bush's and Hillary Clinton's presidential campaigns; the efficacy of various proposed solutions to the failed war on drugs; the poor - quality televised news program for teens (with lots of advertising) that has quietly seeped into many of America's public schools; an early exploration of deceptive practices by the credit card industry; a study of ecosystem destruction in Irian Jaya, one of the world's last substantial rain forests.

The Valeant spokeswoman wrote us that the first alcohol interaction study actually began enrolling patients and argued the drug maker is not responsible if that information is not reflected on the FDA website.

In a new study based on mice, scientists at Lancaster University found that a drug that goes after three diabetes - related targets «significantly reversed the memory deficit» in mice who got the drug, as measured by their performance in a maze test when compared to mice who didn't get the drug.

And Marathon barely did any actual clinical legwork to get the drug cleared for Duchenne — it relied on 1990 - era clinical trial data before tacking on just enough study material to win an approval that doesn't even address the root cause of the disease.

He periodically briefs state politicians on his work, and this year he got a federal grant to study prescription drug monitoring programs.

On May 30, Gilead said it found in four late - stage studies that its its drug, bictegravir, wasn't inferior to ViiV's dolutegravir.

But while thousands of clinical trials on immunotherapy drugs, of which many are predicted to fail, are springing up, the depth of information on neoantigen vaccines is much shallower: Just two studies on neoantigen vaccines for melanoma, recently profiled in Nature, were completed last year in Boston and Germany.

The study, just published in Science, showed that the creation of what the researchers are calling microtumors can help predict drug effectiveness in cancer patients better than the current standard method of testing the drugs on rodents.

Both in practice and in his research, the Mexico City native is focused on improving the world, whether through studies on social enterprise and microfinance or a TED talk on brand management and Mexican drug cartels that accumulated more than 1 million views.

«The DEA appears to be dragged into this kicking and screaming,» said Sanho Tree, director of the Drug Policy Project at the Institute for Policy Studies, a progressive think tank focused on social - justice issues.

According to a study published last year by the National Bureau of Economic Research, American consumers are spending an estimated extra $ 44 billion a year on brand - name drugs, health care items and pantry goods.

The institute, which includes over 40 laboratories and more than 300 researchers, said the research would focus on modifying a patient's own immune system T - cells to target a tumor, studying ways to boost patient response to current immunotherapy drugs.

But according to the Government Accountability Office (GAO) which did a study in 2013 on the drug shortage, other reasons include a lack of materials to make the drugs, as well as delays in getting government approval for new and experimental drugs.

For industries like healthcare, Larsen points out that various studies have found that the most «satisfied» patients are also those who spent the most on prescription drugs and were 12 percent more likely to be admitted to hospitals.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

In an editorial accompanying the new study, Dr. Wilson Compton of the National Institute on Drug Abuse in Bethesda, Maryland, and colleagues say policymakers need to understand which parts of medical marijuana laws are tied with positive and negative effects.

Those on the payroll of a drug company as clinical advisers may be seen as conflicted, especially (but not only) if that company is funding the study.

(Reuters)- Sage Therapeutics Inc's shares tumbled 23 percent on Tuesday after its drug to treat a life - threatening seizure disorder failed to meet the main goal of a key trial, raising concerns about the future of the study.

According to Living Goods, clients may also be reluctant to buy drugs from other private providers because of the risk of getting a counterfeit medicine.63 Living Goods sent us a study conducted at the midline of its RCT that claims that both availability of counterfeit drugs and drug prices decreased at private retailers in areas where CHPs worked.64 According to the study, about 37 % of private drug shops in the areas it studied sold fake ACT drugs, 65 and availabilty of fake ACTs was about 50 % lower among non-Living Goods sellers in the areas where Living Goods worked.66 Additional results on these potential effects will be made available when the full RCT is published.

Last year, the FDA issued final guidance on the use of real - world data for the development of devices, and FDA Commissioner Scott Gottlieb has pledged to issue guidance on real - world data for both pre-and post-marketing drug studies.

It also asks for data on studies comparing the proposed drug to the approved brand - name drug, called the «reference drug,» and asks for data from studies conducted on the generic drug.

That may come as a surprise amid hand - wringing about the spiraling cost of health care, but two new studies, one from research company IMS Health and one from pharmacy benefit manager Express Scripts, show that the amount of money Americans spend on prescription drugs went down in 2012 for the first time in decades.

On February 24th, the New York - based drug giant announced that Prevenar 13, a drug widely used to prevent infection in children, met its primary endpoint in a post-approval study consisting of 85,000 individuals aged 65 and older.

Alkermes is partnering with Biogen on ALKS 8700, a drug for multiple sclerosis that improves on Biogen's $ 4 billion Tecfidera, and a tolerability study should read out in the first half of 2018, with submission to the FDA expected in the the second half.

The drug is presently in a third late - stage study, and Alkermes said it plans on updating investors on the progress of this remaining study later this year.

What: Shares of Alkermes (NASDAQ: ALKS) shed up to 43 % of their value on extraordinary volume in early morning trading today after the company announced that its orally administered drug ALKS - 5461, indicated for major depressive disorder (MDD), failed to meet its primary endpoints in two late - stage studies.

Celgene will help fund a study with BeiGene's lung cancer hopeful, tislelizumab, and in return pay BeiGene royalties on any U.S. sales of the drug.

I know that what maybe important to me might not be important to another but someone recently did a study to find out that the part in the brain that «lights up» when some people who play video - games excessively, is the same that «lights up» when folks get high on drugs....

The study, published in the January edition of the British Journal of Psychiatry, says spiritual but not religious people, as opposed to people who are religious, agnostic or atheist, were more likely to develop a «mental disorder,» «be dependent on drugs» and «have abnormal eating attitudes,» like bulimia and anorexia.

There I learned of 17 Protestant and Roman Catholic clergy whose weekly time for breakfast, prayer and textual study is life - giving for ministries that take on poverty, crime, drugs and AIDS.

It ignores studies of the average life span of homosexuals, the rampant promiscuity, drug use, depression, and so on.

According to a Government Accounting Office study, the U.S. Air Force spent $ 3.3 million on drug interdiction, using sophisticated AWACS surveillance planes over a 15 - month period ending in 1987.

The San Francisco study actually found that 94 percent of panhandlers spend whatever money they get on food, compared to just 44 percent who spend it on drugs or alcohol.

Based on the experience of Prohibition and various studies, drug use would not increase significantly.

I have a bachelor degree in social studies and worked for many years with people at group homes in Denmark and experienced everyday how focused the doctors were on trying to cure the patients with drugs.

Lowers Blood Pressure: A 2013 study published in Drug Research examined the effects of yumberry (Myrica rubra) on the cardiovascular system of rats.

RBT contracted Medicus Research, the premier contract research organization for the Dietary Supplement, Functional Foods and Botanical Drug industries, to perform a comprehensive analysis of independent studies conducted on behalf of RBT to substantiate numerous important health claims for its proprietary and process patented rice bran derivatives and products.

In this study, and in opposition to findings elsewhere, higher levels of social support were associated with greater depressive symptomatology, leading researchers to speculate that for low - income men the perceived costs of reciprocity may have deterred them from utilizing available support; or that peer groups may have influenced their alcohol or drug use, or placed demands on their resources (Anderson et al, 2005).